Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All montelukast studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMontelukastMontelukast (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Montelukast’s ability to fight COVID-19 infection

Bozek et al., Journal of Asthma, doi:10.1080/02770903.2020.1786112
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization 91% Improvement Relative Risk Case 82% Montelukast for COVID-19  Bozek et al.  Prophylaxis Is prophylaxis with montelukast beneficial for COVID-19? Retrospective 445 patients in Germany (March - April 2020) Lower hospitalization (p=0.019) and fewer cases (p=0.0037) c19early.org Bozek et al., J. Asthma, September 2020 Favorsmontelukast Favorscontrol 0 0.5 1 1.5 2+
28th treatment shown to reduce risk in November 2021
 
*, now with p = 0.0045 from 8 studies.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 77 treatments. c19early.org
Retrospective 445 elderly patients with severe asthma showing reduced risk of COVID-19 infection with montelukast treatment.
risk of hospitalization, 91.0% lower, RR 0.09, p = 0.02, treatment 1 of 327 (0.3%), control 4 of 118 (3.4%), NNT 32.
risk of case, 82.0% lower, RR 0.18, p = 0.004, treatment 4 of 327 (1.2%), control 8 of 118 (6.8%), NNT 18.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bozek et al., 17 Sep 2020, retrospective, Germany, peer-reviewed, 2 authors, study period March 2020 - April 2020. Contact: andrzejbozek@o2.pl.
This PaperMontelukastAll
Montelukast’s ability to fight COVID-19 infection
Andrzej Bozek, Janne Winterstein
Journal of Asthma, doi:10.1080/02770903.2020.1786112
Montelukast can be effective in the treatment of SARS-CoV-2 infection.
References
Bisgaard, Montelukast in RSV-bronchiolitis, Am J Respir Crit Care Med
Bozek, Warkocka-Szoltysek, Filipowska-Gronska, Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients, J Asthma
Crimi, Pagano, Palermo, Mastruzzo, Prosperini et al., Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin A-induced bronchoconstriction, J Allergy Clin Immunol
Fitzgerald, Mellis, Leukotriene receptor antagonists in virus-induced wheezing : evidence to date, Treat Respir Med
Han, Jia, Takeda, Shiraishi, Okamoto et al., Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus, Am J Respir Crit Care Med
Kloepfer, Demore, Vrtis, Swenson, Gaworski et al., Effects of montelukast on patients with asthma after experimental inoculation with human rhinovirus 16, Ann Allergy Asthma Immunol
Peng, Chen, Yang, Liu, Systematic Review of Montelukast's Efficacy for Preventing Post-Bronchiolitis Wheezing, Pediatr Allergy Immunol, doi:10.1111/pai.12124
{ 'indexed': {'date-parts': [[2024, 5, 21]], 'date-time': '2024-05-21T18:25:49Z', 'timestamp': 1716315949917}, 'reference-count': 7, 'publisher': 'Informa UK Limited', 'issue': '10', 'content-domain': {'domain': ['www.tandfonline.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 10, 3]]}, 'DOI': '10.1080/02770903.2020.1786112', 'type': 'journal-article', 'created': {'date-parts': [[2020, 6, 26]], 'date-time': '2020-06-26T07:43:38Z', 'timestamp': 1593157418000}, 'page': '1348-1349', 'update-policy': 'http://dx.doi.org/10.1080/tandf_crossmark_01', 'source': 'Crossref', 'is-referenced-by-count': 18, 'title': 'Montelukast’s ability to fight COVID-19 infection', 'prefix': '10.1080', 'volume': '58', 'author': [ { 'given': 'Andrzej', 'family': 'Bozek', 'sequence': 'first', 'affiliation': [ { 'name': 'Clinical Department of Internal Disease, Dermatology and ' 'Allergology, Medical University of Silesia, Katowice, Poland'}]}, { 'given': 'Janne', 'family': 'Winterstein', 'sequence': 'additional', 'affiliation': [{'name': 'Allergy Outpatient Clinic, Munchen, Germany'}]}], 'member': '301', 'published-online': {'date-parts': [[2020, 9, 17]]}, 'reference': [ {'key': 'CIT0001', 'doi-asserted-by': 'publisher', 'DOI': '10.1164/rccm.200912-1811OC'}, { 'issue': '3', 'key': 'CIT0002', 'doi-asserted-by': 'crossref', 'first-page': '252', 'DOI': '10.1016/j.anai.2010.11.021', 'volume': '106', 'author': 'Kloepfer KM', 'year': '2011', 'journal-title': 'Ann Allergy Asthma Immunol'}, {'key': 'CIT0003', 'doi-asserted-by': 'publisher', 'DOI': '10.1067/mai.2003.161'}, { 'key': 'CIT0004', 'doi-asserted-by': 'publisher', 'DOI': '10.2165/00151829-200605060-00006'}, {'key': 'CIT0005', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/pai.12124'}, { 'issue': '4', 'key': 'CIT0006', 'doi-asserted-by': 'crossref', 'first-page': '542', 'DOI': '10.1164/ajrccm.169.4.952', 'volume': '169', 'author': 'Bisgaard H.', 'year': '2004', 'journal-title': 'Am J Respir Crit Care Med'}, {'key': 'CIT0007', 'doi-asserted-by': 'publisher', 'DOI': '10.3109/02770903.2012.680638'}], 'container-title': 'Journal of Asthma', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.tandfonline.com/doi/pdf/10.1080/02770903.2020.1786112', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 9, 2]], 'date-time': '2021-09-02T13:15:56Z', 'timestamp': 1630588556000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.tandfonline.com/doi/full/10.1080/02770903.2020.1786112'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9, 17]]}, 'references-count': 7, 'journal-issue': {'issue': '10', 'published-print': {'date-parts': [[2021, 10, 3]]}}, 'alternative-id': ['10.1080/02770903.2020.1786112'], 'URL': 'http://dx.doi.org/10.1080/02770903.2020.1786112', 'relation': {}, 'ISSN': ['0277-0903', '1532-4303'], 'subject': [], 'container-title-short': 'Journal of Asthma', 'published': {'date-parts': [[2020, 9, 17]]}, 'assertion': [ { 'value': 'The publishing and review policy for this title is described in its Aims & ' 'Scope.', 'order': 1, 'name': 'peerreview_statement', 'label': 'Peer Review Statement'}, { 'value': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijas20', 'URL': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijas20', 'order': 2, 'name': 'aims_and_scope_url', 'label': 'Aim & Scope'}, { 'value': '2020-04-29', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-06-05', 'order': 1, 'name': 'revised', 'label': 'Revised', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-06-17', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-09-17', 'order': 3, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit